Início › Câncer de Pulmão de Não Pequenas Células › Maine

Ensaios clínicos de Câncer de Pulmão de Não Pequenas Células em Maine

16 estudos para Câncer de Pulmão de Não Pequenas Células estão buscando participantes em locais em Maine.

Cidades em Maine

Texto oficial do estudo (Inglês)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Harold Alfond Center for Cancer Care, Augusta
MaineHealth Waldo Hospital, Belfast
Lafayette Family Cancer Center-EMMC, Brewer
e mais 5

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT04267848

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

MaineHealth Coastal Cancer Treatment Center, Bath
MaineHealth Cancer Care and IV Therapy - Brunswick, Brunswick
MaineHealth Maine Medical Center - Portland, Portland
e mais 3

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT07293247

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

New England Cancer Specialists ( Site 0139), Westbrook

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT07190248

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Harold Alfond Center for Cancer Care, Augusta
MaineHealth Maine Medical Center- Scarborough, Scarborough
MaineHealth Cancer Care and IV Therapy - South Portland, South Portland

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06498635

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

New England Cancer Specialists ( Site 0095), Westbrook

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06312137

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Maine Medical Center, Portland
MaineHealth Cancer Care and Blood Disorders Scarborough, Scarborough
MaineHealth Cancer Care and IV Therapy - South Portland, South Portland

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06758401

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

New England Cancer Specialists ( Site 0143), Westbrook

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06170788

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

New England Cancer Specialists, Westbrook

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 24 de set. de 2026 · NCT06890598

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site, Scarborough

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 18 de set. de 2026 · NCT06692738

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Research Site, South Portland

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 4 de set. de 2026 · NCT07291037

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Lafayette Family Cancer Center-EMMC, Brewer

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 3 de jun. de 2026 · NCT05642572

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Lafayette Family Cancer Center-EMMC, Brewer

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 6 de mai. de 2026 · NCT06116682

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Lafayette Family Cancer Center-EMMC, Brewer

RecrutandoFase 2

18 Minutes · Todos os sexos · Atualizado em 5 de mai. de 2026 · NCT06031688

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Harold Alfond Center for Cancer Care, Augusta
MaineHealth Waldo Hospital, Belfast
Lafayette Family Cancer Center-EMMC, Brewer
e mais 5

RecrutandoFase 2/3

Idades 18 e acima · Todos os sexos · Atualizado em 5 de mai. de 2026 · NCT06616584

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Harold Alfond Center for Cancer Care, Augusta
MaineHealth Waldo Hospital, Belfast
MaineHealth Maine Medical Center - Biddeford, Biddeford
e mais 7

RecrutandoEstudo observacional

Idades 18 e acima · Todos os sexos · Atualizado em 17 de mar. de 2026 · NCT06418204

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio SYNERGY-AI site, Scarborough

RecrutandoEstudo observacional

Todas as idades · Todos os sexos · Atualizado em 28 de out. de 2025 · NCT03452774

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.